Lonza Speciality Ingredients, will manufacture and supply a human milk oligosaccharide (HMO) as part of a deal with Copenhagen-based DuPont Nutrition & Health. This strategic manufacturing collaboration will allow DuPont to accelerate commercialisation of the ingredient to the market.
With an ever-increasing global population, many are of the opinion that demand for infant nutrition products will increase. This would include HMOs for infant formula.
Through the agreement, DuPont will be able to obtain a significant volume and reliable supply chain to continue to meet this increased demand.
Erasmo Schutzer, President of Lonza’s Consumer Health Division, said: “Partnering with DuPont, Lonza will apply its leading science and biotechnology expertise in consumer health and nutrition applications to develop and manufacture superior quality human milk oligosaccharide CARE4U 2’-FL.”
The oligosaccharide at the centre of the partnership is CARE4U 2’-FL. In clinical studies, this compound has been shown to mimic some of the health-promoting effects of HMOs.
